We are live on ! Find out more
LPC

Lion Point Capital Portfolio holdings

AUM $20.9M
1-Year Est. Return 195.52%
This Fund
S&P 500
This Quarter Est. Return
+58.26%
1 Year Est. Return
+195.52%
3 Year Est. Return
+318.83%
5 Year Est. Return
+369%
10 Year Est. Return
+2,361.28%
AUM
$20.9M
AUM Growth
+$4.17M
Cap. Flow
-$463K
Cap. Flow %
-2.22%
Top 10 Hldgs %
55.01%
Holding
35
New
–
Increased
–
Reduced
1
Closed
–

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
CUE icon
Cue Biopharma
CUE
+$463K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CUE icon
1
Cue Biopharma
CUE
$201M
$1.67M 7.99%
52,928
-20,500
-28% -$463K
PRAX icon
2
Praxis Precision Medicines
PRAX
$9.87B
$1.49M 7.13%
4,450
– –
MLTX icon
3
MoonLake Immunotherapeutics
MLTX
$1.27B
$1.31M 6.29%
67,500
– –
FENC icon
4
Fennec Pharmaceuticals
FENC
$435M
$1.21M 5.78%
112,434
– –
RPRX icon
5
Royalty Pharma
RPRX
$28.6B
$1.2M 5.74%
21,400
– –
CMPS
6
Compass Pathways
CMPS
$1.82B
$1.13M 5.41%
80,000
– –
MIST icon
7
Milestone Pharmaceuticals
MIST
$153M
$1.1M 5.26%
820,000
– –
BNTC icon
8
Benitec Biopharma
BNTC
$429M
$830K 3.97%
62,000
– –
SNDX icon
9
Syndax Pharmaceuticals
SNDX
$1.86B
$787K 3.76%
36,000
– –
BHVN icon
10
Biohaven
BHVN
$2.34B
$769K 3.68%
51,700
– –
GERN icon
11
Geron
GERN
$957M
$740K 3.54%
578,000
– –
QURE icon
12
uniQure
QURE
$3.08B
$677K 3.24%
14,700
– –
ARDX icon
13
Ardelyx
ARDX
$963M
$656K 3.14%
128,650
– –
LNTH icon
14
Lantheus
LNTH
$6.59B
$610K 2.92%
5,500
– –
IRON icon
15
Disc Medicine
IRON
$3.04B
$592K 2.83%
8,100
– –
SRPT icon
16
Sarepta Therapeutics
SRPT
$2.34B
$512K 2.45%
28,500
– –
HUMA icon
17
Humacyte
HUMA
$164M
$507K 2.43%
650,000
– –
KURA icon
18
Kura Oncology
KURA
$1.16B
$505K 2.41%
46,000
– –
VTRS icon
19
Viatris
VTRS
$19.4B
$440K 2.1%
27,700
– –
DYN icon
20
Dyne Therapeutics
DYN
$4.56B
$400K 1.91%
18,000
– –
BBIO icon
21
BridgeBio Pharma
BBIO
$14.6B
$372K 1.78%
5,000
– –
EWTX icon
22
Edgewise Therapeutics
EWTX
$4.58B
$370K 1.77%
9,100
– –
PCRX icon
23
Pacira BioSciences
PCRX
$1.05B
$342K 1.64%
13,500
– –
RGNX icon
24
Regenxbio
RGNX
$593M
$319K 1.52%
26,600
– –
RCKT icon
25
Rocket Pharmaceuticals
RCKT
$411M
$294K 1.41%
86,000
– –
1
2

Similar funds

SCM
Stadium Capital Management New Canaan, Connecticut $21M AUM 6.45% 1-Year Est. Return
MPW
MGO Private Wealth Irvine, California $20.7M AUM 18.57% 1-Year Est. Return
FS
Financially Speaking Greenwood Village, Colorado $20.6M AUM 16.79% 1-Year Est. Return
VAM
Vazirani Asset Management New York $20.3M AUM 79.33% 1-Year Est. Return
SPC
Stone Point Capital Greenwich, Connecticut $21.7M AUM 48.55% 1-Year Est. Return
SCM
Semanteon Capital Management Newton, Massachusetts $22.2M AUM 53.69% 1-Year Est. Return
HIIL
HS Investments III Ltd St. Peter Port $22.3M AUM
PMAM
Penn Mutual Asset Management Conshohocken, Pennsylvania $19.5M AUM 3.07% 1-Year Est. Return

Lion Point Capital's Q2 2026 Portfolio in Review

As of Q2 2026, Lion Point Capital held 35 positions worth $20.9M, up 25% from $16.7M the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Trading was light in Q2 2026: portfolio turnover was 0%. Lion Point Capital opened no new positions and made no exits, leaving the 35-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Lion Point Capital's biggest Q2 2026 reduction was Cue Biopharma, cutting an estimated $463K.
  • Lion Point Capital's ten largest holdings make up 55% of its $20.9M portfolio in Q2 2026.
  • Lion Point Capital opened 0 new positions and closed 0 in Q2 2026.
  • Lion Point Capital's portfolio value rose 25% quarter-over-quarter to $20.9M.

Based on Lion Point Capital's 13F filing for Q2 2026, filed 14 Aug 2026.